Esperion Therapeutics ESPR Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total operating expenses?
- Esperion Therapeutics (ESPR) reported total operating expenses of $86.69M in Q1 2026.
- How has Esperion Therapeutics's total operating expenses changed year-over-year?
- Esperion Therapeutics's total operating expenses decreased by 0.5% year-over-year, from $87.09M to $86.69M.
- What is the long-term trend for Esperion Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Esperion Therapeutics's total operating expenses has grown at a 3.0% compound annual growth rate (CAGR), from $305.18M to $342.86M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.